Ignoranti, quem portum petat, nullus suus ventus est.

LUCIUS ANNAEUS SENECA (Minor)

OUR MISSION

Personather was founded in 2015 to develop innovative anti-cancer therapies and diagnostic tools based on personalized medicine. The company develops entirely original therapies. Designed by the Personather team, these therapies focus on targeting and eliminating only cancer cells. Team members have ten years of experience in designing anti-cancer therapies and twenty years of experience in regenerative medicine (stem cells). All projects are carried out by an experienced team of scientists representing various scientific fields (e.g., bioinformatics, molecular and cellular biology, and genetic engineering) while utilizing the latest technological advancements.

OUR VISION

DEVELOPMENT OF A THERAPY THAT DESTROYS ONLY CANCER CELLS AND IS HARMLESS TO NORMAL CELLS

    1. TARGET

    2. INVESTMENT

    3. SCENARIOS

    4. SERVICES

    1. The development of therapies specifically directed against tumor cells is possible if the therapeutic target is present only in cancer cells.

    2. The swift realization of this goal may occur, among other factors, due to the investment in the Personather Company and its project (intermediate preclinical trials). One of the projects has funding from the NCRD - National Centre for Research and Development.

    3. Implementation of own pre-clinical tests by Personather. Implementation of additional projects.

    4. The company carries out service and sales activities, generating instant income

KEY INFORMATION

  • RAPID PROGRESS
  • EXPERIENCE
  • After three years of implementation, Personather has prepared several patent applications for its first project (RASG12V). Personather started three additional projects.
  • The founders of the company gained experience in other biotech companies that launched over a dozen biotechnological products, provided services for several entities, and had their own production facility. The team has fifteen years of experience in stem cell research and twenty years of experience in oncology.
  • REVENUE
  • KNOW-HOW
  • TEAM IP
  • In 2017, 2018, and 2019, Personather achieved service income that enabled it to undertake the first NCRD project. In July 2019, Personather's service income was higher than that of all of 2018 combined. Income from technology sales should be counted in the tens of millions.
  • The team's know-how allows for the conduction of projects and the provision of services. New projects can be initiated.
    Stem cell and oncology experience, as well as biotechnology service experience, are available.
  • The co-founders of Personather, as legal entities, own several patents, including international ones and multiple patent applications. The company holds shares in one patent application from outside the NCRD project. Personather has applied for several independent patents (RAS mutants anticancer therapy) and two utility models.

OUR PROJECTS

FUTURE
of the
COMPANY
PERSONATHER IS ABOUT TO DESIGN AN ABSOLUTELY ORIGINAL ANTICANCER THERAPY, OPENING THE POSSIBILITY OF ENTERING CLINICAL TRIALS.
  • Subsequent applications for public co-financing (NCRD) of projects concerning the development of targeted anti-cancer molecules.
  • First technology revenue is achievable within two years from now.
  • Continuation of services for other R&D entities, providing instant income.

Project “Development of anticancer targeted therapy based on small molecules regulating mutated RAS protein G12V” is co-funded by the European Regional Development Fund under the Operational Programme Smart Growth 2014 - 2020.

Project value - 5,979,640.00 PLN,
Eligible expenses - 5,979,640.00 PLN,
Value of EU funding - 4,531,314.95 PLN

OUR SERVICES

Personather participates in designing a new antiviral therapy. Modified by the therapy, SPIKE proteins prevent cell infection, and other viral elements cannot self-organize (self-assemble) into dangerous virions. Personather invests the income generated from the antiviral project to design an anti-cancer therapy.

https://dg-nika.ch/index-en.html

MANAGEMENT TEAM

Prof. Piotr Rieske
Chairman of the Board, Personather Ltd., CTO, Shareholder

In 2008, Prof . Rieske was one of the founders of the biotech company Celther Polska Ltd., where he currently holds the position of CTO. He participated in several commercialization efforts (stem cell technologies, biodegradable bandages, and numerous scientific research tools). In 2016, he founded Personather Ltd.
Prof. Piotr Rieske earned his PhD in 1998, two years after receiving his MSc. He took part in a postdoctoral internship at Thomas Jefferson University, Hahnemann University Hospital, and Temple University in Philadelphia. In Poland, he was involved in cancer molecular biology research. Since 2012, he has been the Chief of the Department of Tumor Biology at the Medical University of Lodz. In 2013, he was awarded a full professorship.
Prof. Rieske is the author of 66 scientific publications, 4 patents, and 17 patent applications (involving 7 new anticancer therapies).
Ewelina Stoczyńska -Fidelus
PhD, hab.
Shareholder, Cellular / Molecular Biologist

Ewelina graduated in Molecular Genetics from the University of Lodz, Poland, and earned her PhD in the Department of Tumor Biology at the Medical University of Lodz, where she currently holds the position of adjunct (associate professor). During her PhD, she participated in a scientific fellowship at Temple University in Philadelphia (USA) and was distinguished in the third edition of the Polish Scientific Foundation scholarship program for PhD students.
In 2015, she co-founded Personather Ltd., a biotech company, where she currently serves as Project Scientific Manager.
Ewelina is the author of 29 scientific publications, 17 patent applications, and 4 patents. She specializes in molecular oncology.

SCIENTIFIC TEAM

The team is complemented by specialists in cell and molecular biology, and genetic engineering, as well as PhD students.
Fifteen employees have participated in the Personather project so far.

OUR AWARDS

It's our great pleasure and privilege to announce that during the Central European BioForum 2019 Personather received the CEBF Award (Category: Individual Award).

https://www.facebook.com/cebioforum/photos/pcb.2283503015044756/2283497038378687/?type=3&theater

YOU ARE WELCOME TO CONTACT US


phone/fax:
00 48 577 643 986

PERSONATHER Ltd.
R&D Laboratory
Inwestycyjna 7 Street
95-050 Konstantynow Lodzki, Poland

e-mail:
terapiacelowana@gmail.com
piotr.rieske@personather.com
office@personather.com
COPYRIGHT
by PERSONATHER 2021